Effects of flecainide in patients with new SCN5A mutation: Mutation- specific therapy for long-QT syndrome?

Circulation

Volumn 101, Issue 14, 2000, Pages 1698-1706

  Benhorin, J ^a,c   Taub, R ^a   Goldmit, M ^a   Kerem, B ^a   Kass, R S ^b   Windman, I ^a   Medina, A ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c BIKUR CHOLIM HOSPITAL   (Israel)

Author keywords

Genetics; Long QT syndrome; Sodium (ion) channels

Indexed keywords

FLECAINIDE; LIDOCAINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; FEMALE; GENE MUTATION; HEART RATE; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; MALE; PEDIGREE; PRIORITY JOURNAL;

EID: 0034636115     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.14.1698     Document Type: Article

References (35)

1. Schwartz PJ, Periti M, Malliani A. The long QT syndrome. Am Heart J. 1975;89:378-390.
2. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent M, Garson A, Robinson JL, Benhorin J, Choi S. The long-QT syndrome: a prospective longitudinal study of 328 families. Circulation. 1991;84:1136-1144.
3. Benhorin J, Kalman YM, Medina A, Towbin J, Rave-Harel N, Dyer TD, Blagero J, MacCluer JW, Kerem B. Evidence of genetic heterogeneity in the long QT syndrome. Science. 1993;260:1960-1962.
4. Towbin JA, Li H, Taggart RT, Lehmann LH, Schwartz PJ, Satler CA, Ayyagari R, Robinson JL, Moss AJ, Hejtmancik JF. Evidence of genetic heterogeneity in Romano-Ward long-QT syndrome: analysis of 23 families. Circulation. 1994;90:2635-2644.
5. Keating M, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppert M. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science. 1991;252:704-706.
6. Keating M, Dunn C, Atkinson D, Timothy K, Vincent GM, Leppert M. Consistent linkage of the long QT syndrome to the Harvey ras-1 locus on chromosome 11. Am J Hum Genet. 1991;49:1335-1339.
7. Jiang C, Atkinson D, Towbin JA, Splawski I, Lehmann MH, Li H, Timothy K, Taggart RT, Schwartz PJ, Vincent GM, Moss AJ, Keating MT. Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. Nat Genet. 1994;8:141-147.
8. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCNA5 mutations associated with an inherited cardiac arrhythmia, the long QT syndrome. Cell. 1995;80:805-811.
9. Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwartz PJ, Keating MT. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet. 1995;4: 1603-1607.
10. Curran ME, Splawski I, Timothy K, Vincent GM, Green E, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
11. Schott JJ, Charpentier F, Peltier S, Foley P, Drouin E, Bouhour JB, Donnelly P, Vergnaud G, Bachner L, Moisan JP, Le Marec H, Pascal O. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet. 1995;57:1114-1122.
12. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G. KvLQT1 and IsK (minK) proteins assemble to form the Iks cardiac potassium current. Nature. 1996;384:78-80.
13. Splawski I, Tristani-Firouzi M, Lehman MH, Sanguinetti MC, Keating MT. Mutations in the hminK gene cause long QT syndrome and suppress Iks function. Nat Genet 1997;17:338-340.
14. George AL, Varkony TA, Drabkin HA, Knops JF, Finley, WH, Brown GB, Ward DC, Haas M. Assignment of the human heart tetrodotoxin-resistant voltage-gated Na+ channel alpha-subunit gene (SCN5A) to band 3p21. Cytogenet Cell Genet. 1995;68:67-70.
15. Gellens ME, George AL, Chen LQ, Chahine M, Horn R, Barchi RL, Kallen RG. Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc Natl Acad Sci USA. 1992;89:554-558.
16. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM. Multiple mechanisms in the long QT syndrome: current knowledge, gaps, and future directions. Circulation. 1996;94:1996-2012.
17. Kambouris NG, Nuss HB, Johns DC, Tomasseli GF, Marban E, Balser JR. Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel. Circulation. 1998;97:640-644.
18. Bennett PB, Yazawa K, Makita, George AL. Molecular mechanism for an inherited cardiac arrhythmia. Nature (Lond). 1995;376:683-685.
19. Dumaine R, Wang Q, Keating MT, Hartmann HA, Schwartz PJ, Brown AM, Kirsch GE. Multiple mechanisms of Na+ channel-linked long-QT syndrome. Circ Res. 1996;78:916-924.
20. Schwartz PJ, Priori SG, Locati EH, Napolitano C. Cantu F, Towbin JA, Keating MT, Hammoude H, Brown AM, Chen LSK, Colatsky TJ. Long QT syndrome patients with mutations of the SCN5A and HERG genes have a differential response to Na+ channel blockade and to increases in heart rate. Circulation. 1995;92:3381-3386.
21. Rosero SZ, Zareba W, Robinson JL, Moss AJ. Gene-specific therapy for long QT syndrome: QT shortening with lidocaine and tocainide in patients with mutation of the sodium channel gene. Ann Noninv Electrocardiol. 1997;2:274-278.
22. An R-H, Bangalore R, Rosero SZ, Kass RS. Lidocaine block of LQT-3 mutant human Na+ channels. Circ Res. 1996;79:103-108.
23. Benhorin J, Goldmit M, MacCluer JW, Blangero J, Goffen R, Leibovitch A, Rahat A, Wang Q, Medina A, Towbin J, Kerem B. Identification of a new SCN5A mutation associated with the long QT syndrome. Hum Mutat. 1998;12:72-74.
24. 1-subunits. Circ Res. 1998;83:141-146.
25. Wang DW, Yazawa K, George ALJ, Bennet PB. Characterization of human cardiac sodium channel mutations in the congenital long QT syndrome. Proc Natl Acad Sci USA. 1996;93:13200-13205.
26. Balser JR, Nuss HB, Orias DW, Johns DC, Marban E, Tomaselli GF, Lawrence JH. Local anesthetics as effectors of allosteric gating: lidocaine effects on inactivation-deficient rat skeletal muscle Na channels. J Clin Invest. 1996;98:2874-2886.
27. Wang DW, Yazawa K, Makita N, George AL, Bennett PB. Pharmacological targeting of long QT mutant sodium channels. J Clin Invest. 1997;99:1714-1720.
28. Anno T, Hondeghem LM. Interactions of flecainide with guinea pig cardiac sodium channels: importance of activation unblocking to the voltage dependence of recovery. Circ Res. 1990;66:789-803.
29. Campbell TJ, Vaughan-Williams EM. Voltage- and time-dependent depression of maximum rate of depolarization of guinea pig ventricular action potentials by 2 new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res. 1983;17:251-258.
30. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res. 1988;62: 116-126.
31. Antzelevitch C, Sicouri S, Lukas A, Nesterenko VV, Liu DW, Di Diego JM. Regional differences in the electrophysiology of ventricular cells: physiologic and clinical implications. In: Zipes DP, Jaliffe J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 1995:228-245.
32. Krishnan SC, Antzelevitch C. Sodium channel blockade produces opposite electrophysiologic effects in canine ventricular epicardium and endocardium. Circ Res. 1991;68:277-291.
33. Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium: phase 2 reentry? Circulation. 1993;87:562-572.
34. Yeola SW, Synders DJ. Electrophysiological and pharmacological correspondence between Kv4.2 current and rat cardiac transient outward current. Cardiovasc Res. 1997;33:540-547.
35. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol. 1992;20: 1391-1396.